Advanced and experienced hematology and cancer care.
Oncology Specialists of Charlotte Welcomes Dr. Nasfat J. Shehadeh to the practice!
Learn More
Clinical Trials

Oncology Specialists of Charlotte has partnered with DJL Clinical Research, a local investigative site network, which was founded by two independent physicians who have participated in medical research and served patients in Charlotte and Union County for over 35 years.

If you, a family member or a loved one would like to determine eligibility, please have them call or e-mail to inquire: 704-247-9179, jen.ponder@djlresearch.com. Research patients do not have to be patients of the practice.


Non-Small Cell Lung Cancer

The KEYNOTE B36 study is a Phase 2 pilot, single-arm, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Study patients use the device concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC).

Who's Eligible?
  • Diagnosed with stage III or metastatic intrathoracic NSCLC
  • Had a PD-L1 positive (TPS≥1%) tumor
  • Has not received prior treatments for NSCLC (palliative treatment is allowed)
  • Age of 22+
Who's Eligible?
  • Diagnosed with stage III or metastatic intrathoracic NSCLC
  • Had a PD-L1 positive (TPS≥1%) tumor
  • Has not received prior treatments for NSCLC (palliative treatment is allowed)
  • Age of 22+
Non-Small Cell Lung Cancer

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard-of-care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.

Who's Eligible?
  • Patients with a histology-based diagnosis of stage 4 NSCLC
  • Disease progression on or after receiving platinum-based chemotherapy
  • Age of 22+
Who's Eligible?
  • Patients with a histology-based diagnosis of stage 4 NSCLC
  • Disease progression on or after receiving platinum-based chemotherapy
  • Age of 22+
Non-small Cell Lung Cancer

Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pembrolizumab for stage IIIB or IV non-small cell lung cancer (NSCLC).

Who's Eligible?
  • Has a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either non-squamous or squamous histology; mixed histology is allowed)
  • Has completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab
  • Age of 18+
Who's Eligible?
  • Has a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either non-squamous or squamous histology; mixed histology is allowed)
  • Has completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab
  • Age of 18+
Cutaneous Squamous Cell Carcinoma

A survivorship edpidemiology study describing the long-term real-world use and effectiveness of cemiplimab for cutaneous squamous cell carcinoma (CSCC).

Who's Eligible?
  • Currently receiving or initiating treatment with cemiplimab for CSCC
  • Continuing treatment with cemiplimab after completing previous clinical trial of cemiplimab
  • Prefer enrollment prior to third dose of cemiplimab
  • Age of 18+
Who's Eligible?
  • Currently receiving or initiating treatment with cemiplimab for CSCC
  • Continuing treatment with cemiplimab after completing previous clinical trial of cemiplimab
  • Prefer enrollment prior to third dose of cemiplimab
  • Age of 18+
Multiple Myeloma

Disease registry encompassing the care of patients with multiple myeloma on panobinostat. Participants will describe current treatment patterns and characterize adverse events in the first or later lines of therapy. Outcomes reported in RECOMM Registry

Who's Eligible?
  • Diagnosed multiple myeloma
  • Started Farydak within 60 days of enrollment
  • Cannot have diagnosis with any B-cell malignancy other than myeloma
  • Age of 18+
Who's Eligible?
  • Diagnosed multiple myeloma
  • Started Farydak within 60 days of enrollment
  • Cannot have diagnosis with any B-cell malignancy other than myeloma
  • Age of 18+
Subscribe to our Newsletter!

Signup today for free and be the first to get notified on new updates.